Jacob J. Adashek, DO University of South Florida, H. Lee Moffitt Cancer Center and Research Institute discusses the AARC 2021 Abstract – The Landscape Of 2,706 RET Alterations From 89,754 Adult Patients With Cancer: Clinical Implications.
Abstract
• Mutations and fusions in the activating receptor-tyrosine kinase rearranged during transfection (RET) have been identified as active drivers of oncogenesis in a variety of cancers.
• The FDA has approved selpercatinib and pralsetinib as highly potent and selective RET inhibitors for RE110111 fusion+ NSCLC and selpercatinib for RET+ thyroid cancers.
• A systematic review of RET alterations in pan-cancer adult malignancies is presented here.
Patients and Procedures
• 96,324 samples from 89,754 patients were examined for the prevalence of RET fusions, mutations, and copy number alterations in various cancer types using the AACR Project Genie database version 8 (accessed July 21, 2020).
• The races of the cohort’s samples were 69,962 (72.6%) white, 5,388 (5.6%) black, 4,90 (5.1%) Asian, 163 (0.17%) Native American, 48 (0.05%) Pacific Islander, and 15,854 (16.5%) unknown.
Final Thoughts
• RET fusions are particularly common in a variety of cancers.
• RET missense mutations are found in 2% of cancers.
•The majority of RET missense variants are classified as variants of uncertain significance, reducing precision oncology’s effect on the majority of patients with RET mutations.
Â
